Details of the Drug

General Information of Drug (ID: DM7ZQAT)

• Drug Name: ALZ-801

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 2	[1]

• #Ro5 Violations (Lipinski): 1:
  Molecular Weight (mw); 238.31
  Logarithm of the Partition Coefficient (xlogp); -3
  Rotatable Bond Count (rotbonds); 6
  Hydrogen Bond Donor Count (hbonddonor); 3
  Hydrogen Bond Acceptor Count (hbondacc); 5
• Chemical Identifiers:
  Formula: C8H18N2O4S
  IUPAC Name: 3-[[(2S)-2-amino-3-methylbutanoyl]amino]propane-1-sulfonic acid
  Canonical SMILES: CC(C)[C@@H](C(=O)NCCCS(=O)(=O)O)N
  InChI: InChI=1S/C8H18N2O4S/c1-6(2)7(9)8(11)10-4-3-5-15(12,13)14/h6-7H,3-5,9H2,1-2H3,(H,10,11)(H,12,13,14)/t7-/m0/s1
  InChIKey: NRZRFNYKMSAZBI-ZETCQYMHSA-N
• Cross-matching ID:
  PubChem CID: 25008296
  CAS Number: 1034190-08-3
  TTD ID: D07VAI

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Amyloid beta A4 protein (APP)	TTE4KHA	A4_HUMAN	Inhibitor	[2]

Molecular Expression Atlas of This Drug

• The Studied Disease: Alzheimer disease
• ICD Disease Classification: 8A20

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Amyloid beta A4 protein (APP)	DTT	APP	1.60E-02	-0.07	-0.31

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Oral Clinical Candidate ALZ-801 in Alzheon's pipeline. 2012.